966a66a2-8aac-41e8-8007-88fd92d2e8e8
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.400
- ALLOGRAFT_REJECTION+0.300
- APICAL_JUNCTION+0.300
- CHOLESTEROL_HOMEOSTASIS+0.300
- COAGULATION+0.300
- IL6_JAK_STAT3_SIGNALING+0.300
- INFLAMMATORY_RESPONSE+0.300
- INTERFERON_ALPHA_RESPONSE+0.300
- INTERFERON_GAMMA_RESPONSE+0.300
Top 10 suppressed
- ANDROGEN_RESPONSE-0.500
- PROTEIN_SECRETION-0.400
- UV_RESPONSE_DN-0.400
- G2M_CHECKPOINT-0.300
- MITOTIC_SPINDLE-0.300
- TGF_BETA_SIGNALING-0.300
- MYC_TARGETS_V1-0.200
- E2F_TARGETS-0.100
- HEME_METABOLISM-0.100
- MTORC1_SIGNALING-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD001516_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.871 |
| 2 | d6b7de60-321d-4f6d-82e7-3d5e9598462c | — | — | 0.858 |
| 3 | 131e315e-6653-4199-b653-42b81644dad9 | — | — | 0.844 |
| 4 | SAMN03290885 | — | — | 0.844 |
| 5 | b83a1cf6-50a6-44fa-834d-8b3df88149fa | — | — | 0.835 |
| 6 | MNG718 | — | — | 0.821 |
| 7 | SRR3147742 | — | — | 0.821 |
| 8 | b2b53efa-8a7b-4871-b6bb-6ebfb5cc0cea | — | — | 0.820 |
| 9 | MDT-AP-2585 | Med | Medulloblastoma | 0.814 |
| 10 | fb24d93c-9681-4d45-801f-9dcfd8c5703e | — | — | 0.813 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.400 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.300 | Remibrutinib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| UV_RESPONSE_UP | 0.300 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |